GB0510788D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB0510788D0
GB0510788D0 GB0510788A GB0510788A GB0510788D0 GB 0510788 D0 GB0510788 D0 GB 0510788D0 GB 0510788 A GB0510788 A GB 0510788A GB 0510788 A GB0510788 A GB 0510788A GB 0510788 D0 GB0510788 D0 GB 0510788D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0510788A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0510788A priority Critical patent/GB0510788D0/en
Publication of GB0510788D0 publication Critical patent/GB0510788D0/en
Ceased legal-status Critical Current

Links

GB0510788A 2005-05-26 2005-05-26 Formulation Ceased GB0510788D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0510788A GB0510788D0 (en) 2005-05-26 2005-05-26 Formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0510788A GB0510788D0 (en) 2005-05-26 2005-05-26 Formulation

Publications (1)

Publication Number Publication Date
GB0510788D0 true GB0510788D0 (en) 2005-06-29

Family

ID=34834699

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0510788A Ceased GB0510788D0 (en) 2005-05-26 2005-05-26 Formulation

Country Status (1)

Country Link
GB (1) GB0510788D0 (en)

Similar Documents

Publication Publication Date Title
IL189856A0 (en) New formulation
GB2424581B (en) Formulations
TWI370115B (en) New formulation
PL1879451T3 (en) Innovative formulation
EP1909584A4 (en) Prenylflavonoid formulations
GB0608098D0 (en) Formulation
IL191287A0 (en) Atorvastatin formulation
HK1116776A1 (en) Triazolophthalazines as pde2-inhibitors
GB0526419D0 (en) Formulation
GB0517673D0 (en) Formulation
ZA200707654B (en) Formulations
EP1928469A4 (en) Fulvestrant formulation
GB0625312D0 (en) Formulation
GB0625095D0 (en) Formulation
GB0423565D0 (en) Formulation
GB0520176D0 (en) Use
GB0511190D0 (en) Use
GB0412530D0 (en) Formulation
GB0501030D0 (en) Formulation
GB0502250D0 (en) Use
LT1928232T (en) Solid formulation
GB0612809D0 (en) Formulation
GB0526031D0 (en) Use
GB0526032D0 (en) Use
GB0506035D0 (en) Improved formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)